Literature DB >> 21069482

Cardiovascular risk reduction via increasing HDL cholesterol: the promise of the dal-OUTCOMES Trial.

Kyaw Soe1, Anis Alam, Charles Philip, Edison Ruiz, Keshwar Ramkissoon, Samy I McFarlane.   

Abstract

Entities:  

Year:  2011        PMID: 21069482     DOI: 10.1007/s11892-010-0165-8

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  9 in total

Review 1.  Plasma cholesteryl ester transfer protein.

Authors:  A R Tall
Journal:  J Lipid Res       Date:  1993-08       Impact factor: 5.922

2.  Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins.

Authors:  M L Brown; A Inazu; C B Hesler; L B Agellon; C Mann; M E Whitlock; Y L Marcel; R W Milne; J Koizumi; H Mabuchi
Journal:  Nature       Date:  1989-11-23       Impact factor: 49.962

Review 3.  High-density lipoprotein: is it always atheroprotective?

Authors:  Benjamin J Ansell; Gregg C Fonarow; Alan M Fogelman
Journal:  Curr Atheroscler Rep       Date:  2006-09       Impact factor: 5.113

4.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

5.  Safety and tolerability of dalcetrapib.

Authors:  Evan A Stein; Erik S G Stroes; George Steiner; Brendan M Buckley; Alessandro M Capponi; Tracy Burgess; Eric J Niesor; David Kallend; John J P Kastelein
Journal:  Am J Cardiol       Date:  2009-07-01       Impact factor: 2.778

Review 6.  Established risk factors and coronary artery disease: the Framingham Study.

Authors:  P W Wilson
Journal:  Am J Hypertens       Date:  1994-07       Impact factor: 2.689

7.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

Authors:  W P Castelli; R J Garrison; P W Wilson; R D Abbott; S Kalousdian; W B Kannel
Journal:  JAMA       Date:  1986-11-28       Impact factor: 56.272

8.  High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.

Authors:  Wim A van der Steeg; Ingar Holme; S Matthijs Boekholdt; Mogens Lytken Larsen; Christina Lindahl; Erik S G Stroes; Matti J Tikkanen; Nicholas J Wareham; Ole Faergeman; Anders G Olsson; Terje R Pedersen; Kay-Tee Khaw; John J P Kastelein
Journal:  J Am Coll Cardiol       Date:  2008-02-12       Impact factor: 24.094

9.  Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.

Authors:  M J Forrest; D Bloomfield; R J Briscoe; P N Brown; A-M Cumiskey; J Ehrhart; J C Hershey; W J Keller; X Ma; H E McPherson; E Messina; L B Peterson; W Sharif-Rodriguez; P K S Siegl; P J Sinclair; C P Sparrow; A S Stevenson; S-Y Sun; C Tsai; H Vargas; M Walker; S H West; V White; R F Woltmann
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

  9 in total
  1 in total

Review 1.  Cardiovascular defense challenges at the basic, clinical, and population levels.

Authors:  Jason C Kovacic; Jose M Castellano; Valentin Fuster
Journal:  Ann N Y Acad Sci       Date:  2012-04       Impact factor: 6.499

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.